Guaifenesin
- Generic Name
- Guaifenesin
- Brand Names
- Broncotron, Bronkaid, Cheracol D, Cheratussin, Cheratussin Dac, Codar Gf, Coricidin Hbp Chest Congestion, DM, Deconex, Delsym Cough Plus Chest Congestion DM, Despec Reformulated Jun 2008, Diabetic Tussin DM, Diabetic Tussin EX, Diphen, Entex Lq, Entex T, G-zyncof, Gilphex, M-clear Wc, Mar-cof Cg, Mucinex, Mucinex Children's Cough, Mucinex Cough, Mucinex D, Mucinex DM, Mucinex Stuffy Nose & Cold, Ninjacof Xg, Obredon, Pediacare Children's Cough and Congestion, Refenesen, Refenesen PE, Rescon-GG, Robafen, Robafen DM, Robitussin Chest Congestion, Robitussin Cough & Congestion, Robitussin Maximum Strength Cough Plus Chest Congestion DM, Safetussin DM, Scot-tussin, Scot-tussin DM, Siltussin, Tusnel C, Tusnel Diabetic
- Drug Type
- Small Molecule
- Chemical Formula
- C10H14O4
- CAS Number
- 93-14-1
- Unique Ingredient Identifier
- 495W7451VQ
- Background
Guaifenesin possesses a storied history, having been originally formally approved by the US FDA in 1952 and continues to be one of very few - if not perhaps the only drug that is readily available and used as an expectorant . Since that time the agent has been a combination component of various prescription and non-prescription over-the-counter cough and col...
- Indication
Guaifenesin is an expectorant that is indicated for providing temporary symptomatic relief from congested chests and coughs which may be due to a cold, bronchitis, and/or other breathing illnesses .
- Associated Conditions
- Allergic Reaction, Allergy to Tree Pollen, Asthma, Asthma, Allergic, Bronchial Asthma, Bronchitis, Bronchospasm, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Common Cold, Cough, Cough caused by Common Cold, Coughing caused by Allergies, Coughing caused by Flu caused by Influenza, Drug Allergy, Emphysema, Fever, Flu caused by Influenza, Food Allergy, Headache, House dust allergy, Irritative cough, Laryngitis, Nasal Congestion, Nasal Congestion caused by Common Cold, Phlegm, Productive cough, Rash, Rhinorrhoea, Sneezing, Sore Throat, Tracheitis, Urticaria, Whooping Cough, Acute Rhinitis, Chest congestion, Chills occurring with fever, Dry cough, Excess mucus or phlegm, Mild to moderate pain, Minor aches and pains
- Associated Therapies
- Airway secretion clearance therapy, Expectorant
FDA to Finally Ban Controversial Ingredient in Popular Decongestants
The FDA proposes removing oral phenylephrine from decongestants due to its ineffectiveness, impacting $1.76 billion market. Popular products like Advil Sinus, Sudafed PE, Vicks DayQuil, and Tylenol Cold & Flu may be affected. Phenylephrine, once deemed effective in 1976, was criticized for lack of efficacy in 2005 and 2007, leading to ongoing debate. The FDA's decision follows recent trials confirming its ineffectiveness at any dose.
FDA Suggests Removing Nonprescription Decongestant from Market
The FDA proposes removing nonprescription drugs containing phenylephrine from shelves due to its ineffectiveness as a nasal decongestant, based on recent and historical research. This follows advisory committee votes against its efficacy and a review showing it no better than a placebo.
FDA proposes banning oral phenylephrine in decongestants
FDA seeks to ban oral phenylephrine in OTC nasal decongestants due to ineffectiveness; no safety concerns; found in NyQuil, Benadryl, Sudafed, Mucinex; public comment period open.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath